Astellas Pharma Inc. and Mitobridge Inc. have synthesized stimulator of interferon genes protein (STING; TMEM173) antagonists reported to be useful for the treatment of autoimmune diseases, neurodegeneration, type I interferonopathy and Sjögren’s syndrome.

Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have disclosed zwitterionic compounds reported to be useful for the treatment of bacterial infections.

Japan Tobacco Inc. has divulged indazole compounds acting as hematopoietic prostaglandin D synthase (HPGDS) inhibitors reported to be useful for the treatment of chronic obstructive pulmonary disease, Duchenne muscular dystrophy, peripheral arterial disease, allergic rhinitis, sarcopenia and allergic asthma.

Celros Biotech Co. Ltd. has identified hydantoin derivatives acting as cytochrome b-245 heavy chain (CYBB; NOX2) and NADPH oxidase 4 (NOX4) inhibitors with blood-brain barrier permeability and metabolic stability reported to be useful for the treatment of atherosclerosis, Alzheimer’s disease, cirrhosis, diabetes, cancer, glomerulonephritis, psoriasis and rheumatoid arthritis, among others.

Assembly Biosciences Inc. has synthesized benzothiadiazepine compounds reported to be useful for the treatment of hepatitis B and hepatitis D.

Satyarx Pharma Innovations Pvt Ltd. has disclosed novel bicyclic compounds acting as DNA repair protein RAD51 homolog 1 inhibitors reported to be useful for the treatment of cancer.

Biohaven Therapeutics Ltd. has described potassium voltage-gated channel subfamily KQT member 2/3 (KCNQ2/3) activators reported to be useful for the treatment of epilepsy, pain, dyskinesia, schizophrenia, anxiety disorders, stroke, Rett syndrome, substance abuse and dependence, among others.

Ennovabio (Zhejiang) Pharmaceuticals Co. Ltd. and Shanghai Ennova Biopharmaceutical Co. Ltd. have described 5-membered and 6-membered heterocyclic compounds acting as non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of cancer, viral infection, transplant rejection, cardiovascular and inflammatory disorders, and autoimmune, myeloproliferative and metabolic diseases.

Medshine Discovery Inc. has divulged hypoxia inducible factor 2α (HIF-2α; EPAS1) inhibitors reported to be useful for the treatment of cancer.

Lhotse Bio Inc. has identified lysophospholipid LPA1 receptor (LPAR1; EDG2) antagonists reported to be useful for the treatment of cancer, fibrosis, chronic obstructive pulmonary disease, multiple sclerosis, inflammatory disorders, SARS-CoV-2 infection (COVID-19), transplant rejection and osteoporosis, among others.